GlassScriptPhysician profile
Kevin M Bell
NPI 1013387406
$4,484.44
in general payments reported to CMS, 2019-2025
33 companies · $1,644 in 2025
The $1,644 reported for 2025 was more than what 88% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $742 · 2022: $636 · 2023: $869 · 2024: $594 · 2025: $1,644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,097 · Travel and Lodging: $1,010.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,096.80 |
| Travel and Lodging | $1,009.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $1,643.48 | 2024-2025 | Indigo System, Penumbra System |
| Abbvie INC. | $415.95 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $351.77 | 2021-2024 | Breztri, Farxiga |
| Glaxosmithkline, LLC. | $317.27 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $136.97 | 2021-2023 | Jardiance |
| Amgen INC. | $132.82 | 2023-2024 | Otezla, Repatha, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.49 | 2021-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $125.34 | 2021-2023 | |
| Dexcom, INC. | $109.17 | 2023-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $107.94 | 2022-2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Ultragenyx Pharmaceutical INC. | $106.56 | 2023-2024 | Crysvita |
| Pfizer INC. | $106.53 | 2021-2022 | |
| Novo Nordisk INC | $100.51 | 2023-2024 | Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $98.76 | 2022-2023 | Xifaxan, Trulance |
| Sumitomo Pharma America, INC. | $85.20 | 2023 | Gemtesa |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $60.18 | 2023-2024 | Cologuard Collection Kit |
| Astellas Pharma US INC | $58.18 | 2021-2024 | Veozah |
| Inari Medical, INC. | $49.12 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Stryker Corporation | $48.35 | 2025 | Clottriever Bold Catheter |
| Janssen Pharmaceuticals, INC | $39.58 | 2021-2022 | |
| Gilead Sciences, INC. | $35.95 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.49 | 2021-2023 | Trintellix |
| Mylan Specialty L.P. | $33.07 | 2023-2024 | Yupelri |
| Impulse Dynamics (USA) INC. | $20.25 | 2023 | Optimizer |
| Phathom Pharmaceuticals, INC. | $19.06 | 2024 | Voquezna |
| Lucid Diagnostics INC. | $17.39 | 2022 | |
| Eisai INC. | $16.63 | 2021 | |
| Xeris Pharmaceuticals, INC. | $16.23 | 2024 | Gvoke Hypopen |
| Digestive Care, INC. | $15.85 | 2024 | Pertzye |
| Arbor Pharmaceuticals, INC. | $15.73 | 2022 | |
| Paratek Pharmaceuticals, INC. | $14.66 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.67 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $12.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.